Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma

Phase 2 Terminated 47 enrolled National Cancer Institute (NCI)

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase II trial is studying how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with recurrent or progressive glioblastoma. Gamma-secretase/Notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start: 2010-12
Primary completion: 2015-08
Completion: 2015-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RG4733	Small molecule	—	Oral

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma

Summary

Timeline

Drugs

Indications